|

18F-mFBG LAFOV PET/CT Compared to 123I-mIBG Scintigraphy SPECT/CT for Evaluation of Children With Neuroblastoma

RECRUITINGN/ASponsored by Rigshospitalet, Denmark
Actively Recruiting
PhaseN/A
SponsorRigshospitalet, Denmark
Started2022-06-06
Est. completion2025-09-01
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05826158

Summary

This is a study evaluating the positron-emitting radiopharmaceutical 18F-mFBG compared to 123I-mIBG scintigraphy for imaging of neuroblastoma

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

1. An established diagnosis of neuroblastoma based on unequivocal histopathology from tissue obtained at any time prior to enrolment in the trial; OR b) A presumed diagnosis of neuroblastoma based on signs, symptoms, physical examination, imaging findings, and laboratory and genetic test results, including individuals in whom therapy has already been empirically initiated.
2. The subject has undergone or is scheduled to undergo evaluation of neuroblastoma disease status, including 123I-mIBG +/- 7 days to the date of 18F-mFBG imaging, with no therapy between such evaluation.
3. Ability of subject or subject's legal guardian to understand and sign a written informed consent document.

   \-

   Exclusion Criteria:

1\. Pregnancy

\-

Conditions2

CancerNeuroblastoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.